IAP

ASCO 2022 | Ascentage Pharma Releases Updated Data Demonstrating Lisaftoclax's (APG-2575) Therapeutic Potential in Patients with R/R CLL/SLL

Retrieved on: 
Wednesday, June 8, 2022

Ascentage Pharma (6855.HK) is a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases.

Key Points: 
  • Ascentage Pharma (6855.HK) is a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases.
  • On October 28, 2019, Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code 6855.HK.
  • Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death.
  • Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators.

ASCO 2022 | The First Dataset of Olverembatinib (HQP1351) in Patients with GIST Demonstrates Therapeutic Potential with a Clinical Benefit Rate of 83.3%

Retrieved on: 
Tuesday, June 7, 2022

Newly updated activity results of alrizomadlin (APG-115), a novel MDM2/p53 inhibitor, plus pembrolizumab: Phase 2 study in adults and children with various solid tumors.

Key Points: 
  • Newly updated activity results of alrizomadlin (APG-115), a novel MDM2/p53 inhibitor, plus pembrolizumab: Phase 2 study in adults and children with various solid tumors.
  • Olverembatinib can effectively target a spectrum of BCR-ABL mutants, including the T315I mutation.
  • Meanwhile, olverembatinib is being investigated for the treatment of gastrointestinal stromal tumor (GIST) in China.
  • In July 2021, Ascentage Pharma and Innovent Biologics (1801.HK) reached the agreement regarding the joint development and commercialization of olverembatinib in the oncology field in China.

Paddle acquires ProfitWell to automate payments infrastructure for SaaS companies

Retrieved on: 
Wednesday, May 25, 2022

Paddle's complete payments infrastructure for SaaS - which integrates checkout, payment, subscription management, and financial compliance processes - is used by over 3,000 software companies including BlueJeans by Verizon, MacPaw, Framer and TailwindLabs.

Key Points: 
  • Paddle's complete payments infrastructure for SaaS - which integrates checkout, payment, subscription management, and financial compliance processes - is used by over 3,000 software companies including BlueJeans by Verizon, MacPaw, Framer and TailwindLabs.
  • We're delighted to have the opportunity to bring our teams together to build a truly holistic, powerful payments infrastructure at the heart of the SaaS market."
  • Paddle, the payments infrastructure provider for B2B SaaS companies powers hyper-scale growth across acquisition, renewals and expansion.
  • With Paddle, companies are finally able to transform their payments infrastructure into a strategic growth lever to respond faster and more precisely to every growth opportunity.

Paddle acquires ProfitWell to automate payments infrastructure for SaaS companies

Retrieved on: 
Wednesday, May 25, 2022

Paddle's complete payments infrastructure for SaaS - which integrates checkout, payment, subscription management, and financial compliance processes - is used by over 3,000 software companies including BlueJeans by Verizon, MacPaw, Framer and TailwindLabs.

Key Points: 
  • Paddle's complete payments infrastructure for SaaS - which integrates checkout, payment, subscription management, and financial compliance processes - is used by over 3,000 software companies including BlueJeans by Verizon, MacPaw, Framer and TailwindLabs.
  • We're delighted to have the opportunity to bring our teams together to build a truly holistic, powerful payments infrastructure at the heart of the SaaS market."
  • Paddle, the payments infrastructure provider for B2B SaaS companies powers hyper-scale growth across acquisition, renewals and expansion.
  • With Paddle, companies are finally able to transform their payments infrastructure into a strategic growth lever to respond faster and more precisely to every growth opportunity.

iOS Performance Marketing is Back: Singular's SKAN Advanced Analytics Provides Accurate D7 Revenue

Retrieved on: 
Wednesday, May 18, 2022

Today we announce the latest update to SKAN Advanced Analytics, SKAN Cohorts, which returns visibility of critical KPIs that marketers currently lack due to SKAdNetwork limitations.

Key Points: 
  • Today we announce the latest update to SKAN Advanced Analytics, SKAN Cohorts, which returns visibility of critical KPIs that marketers currently lack due to SKAdNetwork limitations.
  • The results in real-world tests are nothing short of astounding, reaching 87% D7 revenue accuracy on average for beta clients.
  • Singular's SKAN Advanced Analytics is built on the first-ever and still industry-leading iOS user acquisition attribution solution that includes SKAN Advanced Reporting, enriching conversion data with aggregated cost and click data from ad networks.
  • More information about Singular's SKAN solution here:
    Singular's next-gen attribution and analytics powers marketers to grow faster by uncovering accurate, granular, and timely performance insights.

Synthetic Biologics Reports Positive Safety Data on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Multiple Ascending Dose Clinical Trial

Retrieved on: 
Tuesday, May 10, 2022

ROCKVILLE, Md., May 10, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced positive safety data from its Phase 1, placebo-controlled, double-blind multiple ascending dose (MAD) clinical trial of SYN-020 intestinal alkaline phosphatase (IAP). The Phase 1 MAD study enrolled 32 healthy adult volunteers into four cohorts with SYN-020 administered orally in doses ranging from 5 mg to 75 mg twice daily for 14 days with a follow-up evaluation at day 35. Each cohort included six subjects who received SYN-020 and two who received placebo. Analyses of preliminary data demonstrated that SYN-020 maintained a favorable safety profile and was well-tolerated across all dose levels. There were a few treatment-related adverse events, and all were mild (grade 1) and resolved without medical intervention. The most common adverse event, constipation, occurred in three out of 24 subjects in the treatment arm and in one out of eight subjects in the placebo arm. No adverse event led to discontinuation of the study drug and there were no serious adverse events. SYN-020 levels were below the limit of quantitation in all plasma samples at all timepoints during the study. Additional analyses, including fecal levels of SYN-020 and anti-drug antibody levels are on-going.

Key Points: 
  • ROCKVILLE, Md., May 10, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced positive safety data from its Phase 1, placebo-controlled, double-blind multiple ascending dose (MAD) clinical trial of SYN-020 intestinal alkaline phosphatase (IAP).
  • Analyses of preliminary data demonstrated that SYN-020 maintained a favorable safety profile and was well-tolerated across all dose levels.
  • Both the previously reported Phase 1 single ascending dose (SAD) study and the current MAD study are intended to support the development of SYN-020 in multiple clinical indications.
  • We are very encouraged by these positive Phase 1 results and look forward to SYN-020s clinical advancement.

Paddle raises $200m to supercharge SaaS companies' global growth

Retrieved on: 
Tuesday, May 10, 2022

The SaaS sector, which was worth $397 billion in 2021, is expected to grow to $692 billion in 2025 .

Key Points: 
  • The SaaS sector, which was worth $397 billion in 2021, is expected to grow to $692 billion in 2025 .
  • By integrating checkout, payment, subscription management, invoicing, international taxes and financial compliance processes, Paddle offers SaaS companies a completely different approach to payments infrastructure.
  • Paddle was created to remove these invisible barriers so that SaaS companies can just focus on building and selling software.
  • By simplifying the payments stack, Paddle enables faster, more sustainable growth for SaaS businesses.

Paddle raises $200m to supercharge SaaS companies' global growth

Retrieved on: 
Tuesday, May 10, 2022

The SaaS sector, which was worth $397 billion in 2021, is expected to grow to $692 billion in 2025 .

Key Points: 
  • The SaaS sector, which was worth $397 billion in 2021, is expected to grow to $692 billion in 2025 .
  • By integrating checkout, payment, subscription management, invoicing, international taxes and financial compliance processes, Paddle offers SaaS companies a completely different approach to payments infrastructure.
  • Paddle was created to remove these invisible barriers so that SaaS companies can just focus on building and selling software.
  • By simplifying the payments stack, Paddle enables faster, more sustainable growth for SaaS businesses.

Synthetic Biologics to Host Conference Call and Webcast to Discuss First Quarter 2022 Operational Highlights and Financial Results

Retrieved on: 
Monday, May 9, 2022

ET to discuss its financial results for the quarter ended March 31, 2022 and provide a corporate update.

Key Points: 
  • ET to discuss its financial results for the quarter ended March 31, 2022 and provide a corporate update.
  • Individuals may participate in the live call via telephone by dialing (877) 451-6152 (domestic) or (201) 389-0879 (international) and using the conference ID: 13729717.
  • Participants are asked to dial in 15 minutes before the start of the call to register.
  • Synthetic Biologics, Inc. (NYSE American: SYN) is a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need.

Synthetic Biologics Announces Presentation on VCN-11, a Novel Oncolytic Adenovirus Designed to Evade Neutralizing Antibodies at the Upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Retrieved on: 
Wednesday, May 4, 2022

ROCKVILLE, Md., May 04, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced an upcoming oral presentation on novel oncolytic adenovirus VCN-11 at the 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), to be held virtually and in-person from May 16-19, 2022 in Washington, D.C.

Key Points: 
  • We are excited to present new data on VCN-11, which should further position us at the forefront of oncolytic virus development, said Steven A. Shallcross, Chief Executive Officer of Synthetic Biologics.
  • VCN-11 is a next-generation adenovirus that is genetically modified to express hyaluronidase and degrade the protective tumor stroma barrier.
  • We look forward to building upon our foundation of compelling proof-of-mechanism data and continuing to advance our oncolytic adenovirus (OV) program through clinical development.
  • The full abstract (# 98 ) is accessible on the ASGCT conference portal and details for the oral presentation are included below.